Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal...
University of PennsylvaniaSep 4 2024 Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal Medicine .
The new study, led by Thomas Wadden, PhD, a professor of Psychology in Psychiatry and the former director of Penn's Center for Weight and Eating Disorders, analyzed data from over 3,500 participants across four major clinical trials. Researchers examined data from the Semaglutide Treatment Effect in People with obesity trials – STEP 1, 2, 3, and 5. These studies were crucial in gaining approval from the FDA to use semaglutide 2.4 mg for obesity.
The study examined changes in depressive symptoms using the Patient Health Questionnaire-9 and assessed suicidal ideation and behavior using the Columbia Suicide Severity Rating Scale. Across the 68-week STEP 1-3 trials, semaglutide-treated participants, as compared to those who received placebo, did not show an increased risk of developing moderately severe symptoms of depression or of suicidal thoughts or behavior. Similar findings were observed in the 104-week STEP 5 study.
Semaglutide Depression Diabetes Drugs Food Medicine Obesity Placebo Type 2 Diabetes Weight Loss
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Study reassures patients about semaglutide safetyTaking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal...
Weiterlesen »
Analysis finds no increased risk of mental health issues among those using semaglutide for weight lossTaking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published in JAMA Internal Medicine.
Weiterlesen »
Is semaglutide use during breastfeeding safe?Researchers found no detectable levels of semaglutide in breast milk, suggesting minimal risk to breastfed infants, but highlighted the need for monitoring maternal nutrition and milk production.
Weiterlesen »
Semaglutide cuts death rates from cardiovascular disease and COVID-19Patients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, finds.
Weiterlesen »
Semaglutide's impact on cardiovascular health expands beyond weight lossSemaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19 related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC, the flagship journal of the...
Weiterlesen »
Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesitySemaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, according to a new study published in JACC, the flagship journal of the American College of Cardiology.
Weiterlesen »